Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Anastrozole; Celecoxib
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 11 Apr 2021 Results of a secondary analysis of large adjuvant endocrine therapy trials (MA.17, MA.17R and MA.27) quantify the impact of competing risks on estimates of disease recurrence and benefit from therapypublished in the European Journal of Cancer
    • 20 Dec 2017 Random assignment to celecoxib was discontinued in 2004 after randomisation of 1622 patients and these patients remained on study and were followed according to study protocol with inclusion in the comparison of exemestane versus anastrozole, according to results published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top